Search for drugs:
Typing the drug name to query
DEFERASIROX
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac Electrophysiology
- At the maximum approved recommended dose, deferasirox does not prolong the QT interval to any clinically relevant extent.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
6
24086
Other ADRs
71608
38309979
Odds Ratio = 0.134
Drug Property Information
ATC Code(s):
- V03AC03 - deferasirox
- V03AC - Iron chelating agents
- V03A - ALL OTHER THERAPEUTIC PRODUCTS
- V03 - ALL OTHER THERAPEUTIC PRODUCTS
- V - VARIOUS
Active Ingredient:DEFERASIROX
Active Ingredient UNII:V8G4MOF2V9
Drugbank ID:DB01609
PubChem Compound:5493381
CTD ID:D000077588
PharmGKB:PA164760843
CAS Number:201530-41-8
Dosage Form(s):tablet, film coated
Route(s) Of Administrator:oral
Daily Dose:
Chemical Structure: 
SMILE Code:
OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O
OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O
Reference
1: Deferasirox does not induce QT/QTc-prolongation in healthy subjects.
[Sechaud R,Dumortier T,Balez S]Int J Clin Pharmacol Ther,2009 May;47(5):321-7. PMID: 19473594
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.